Back to Journals » OncoTargets and Therapy » Volume 10

Niclosamide inhibition of STAT3 synergizes with erlotinib in human colon cancer

Authors Shi L, Zheng H, Hu W, Zhou B, Dai X, Zhang Y, Liu Z, Wu X, Zhao C, Liang G

Received 5 December 2016

Accepted for publication 20 January 2017

Published 23 March 2017 Volume 2017:10 Pages 1767—1776

DOI https://doi.org/10.2147/OTT.S129449

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Ashok Kumar Pandurangan

Peer reviewer comments 2

Editor who approved publication: Dr XuYu Yang

Lingyi Shi,1,* Hailun Zheng,1,* Wanle Hu,2 Bin Zhou,2 Xuanxuan Dai,3 Yi Zhang,3 Zhiguo Liu,1 Xiaoping Wu,1 Chengguang Zhao,1 Guang Liang1

1Chemical Biology Research Center, School of Pharmaceutical Sciences, 2Department of Coloproctology, The Second Affiliated Hospital and Yuying Children’s Hospital, 3Department of Oncological Surgery, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, People’s Republic of China

*These authors contributed equally to this work

Abstract: Niclosamide, an anthelmintic drug approved by the US Food and Drug Administration against cestodes, is used to treat tapeworm infection. In this study, we show that niclosamide can potentially inhibit signal transducer and activator of transcription 3 (STAT3) in colon cancer cell lines. Combined inhibition of epidermal growth factor receptor and STAT3 by erlotinib and niclosamide synergistically induces apoptosis and antiproliferation in colon cancer cell lines. Our findings suggest that erlotinib and niclosamide combination provides an effective therapeutic approach to improving the prognosis of colon cancer.

Keywords: STAT3, EGFR, erlotinib, niclosamide, colon cancer

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Nifuratel, a novel STAT3 inhibitor with potent activity against human gastric cancer cells

Zheng HL, Hong H, Zhang LL, Cai X, Hu M, Cai YP, Zhou B, Lin JY, Zhao CG, Hu WL

Cancer Management and Research 2017, 9:565-572

Published Date: 1 November 2017

Curcumin sensitizes human gastric cancer cells to 5-fluorouracil through inhibition of the NFκB survival-signaling pathway

Kang Y, Hu W, Bai E, Zheng H, Liu Z, Wu J, Jin R, Zhao C, Liang G

OncoTargets and Therapy 2016, 9:7373-7384

Published Date: 5 December 2016

Synthesis and biological evaluation of a novel class of curcumin analogs as anti-inflammatory agents for prevention and treatment of sepsis in mouse model

Zhao C, Zhang Y, Zou P, Wang J, He W, Shi D, Li H, Liang G, Yang S

Drug Design, Development and Therapy 2015, 9:1663-1678

Published Date: 18 March 2015